Sanofi gains first approval for nanobody-based medicine Cablivi

3 September 2018
2019_biotech_test_vial_discovery_big

French pharma major Sanofi (Euronext: SAN) has been granted EU approval to market Cablivi (caplacizumab) for episodes of a rare and life-threatening genetic disorder, acquired thrombotic thrombocytopenic purpura (aTTP).

Cablivi, an anti-vWF nanobody, is the first product specifically indicated for the treatment of aTTP, and the company's first nanobody-based medicine to receive approval.

The current standard-of-care treatment, daily plasma exchange (PEX) and immunosuppression, is not enough to improve prevent mortality rates of up to 20%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology